1.Executive Summary
The Energy Shock Returned
Research window
2026-03-01 to 2026-03-31
Data vintage
Retrospective edition, researched through 2026-08-05
Linked sources
29 primary and attributable references
Mood 1.8 / 10 · Deeply bearish — energy shock
-1.3 vs. FebruaryMarch removed the ambiguity from February. German chemical companies entered the month with thin orders and low utilization. They left it with a renewed energy shock, record-low employment expectations, and a wage agreement designed around job protection rather than purchasing power.
This was not a replay of 2022. Gas and electricity prices remained below their crisis peaks, and some Asian competitors faced even sharper supply constraints. The mechanism was nevertheless familiar: higher oil, naphtha, gas, transport, and insurance costs met a market too weak to absorb them. Producers announced price increases, but pricing power was uneven. Where cost pass-through failed, the adjustment shifted to jobs, output, and capital spending.
Monitoring note. Events are assigned to March. Statistics published in early April are used as retrospective measurements. The Mood Index is an editorial composite: demand and output 40%, energy and inputs 20%, company decisions 20%, regulation 10%, and capital-market narrative 10%.
Source scope includes VCI, Destatis, and the Federal Ministry for Economic Affairs and Energy (BMWE, formerly BMWK). No ministry production series superseded the VCI/Destatis sector data in this window.
Mood Index: 1.8 / 10 — Deeply bearish, energy shock
Change from February: -1.3
| Indicator | March reading | Interpretation |
|---|---|---|
| ifo chemical business climate | -25.0 | February stabilization reversed |
| ifo current situation | -31.9 | Weak order books met higher costs |
| ifo expectations | -17.9 | No confidence in rapid normalization |
| Chemical employment expectations | -32.1 | Historical low in the series |
| Producer energy prices | +7.5% m/m; -3.2% y/y | Acute monthly shock, still below prior-year base |
Top three events
- War-driven input inflation hit the sector at full force. March producer energy prices rose 7.5% month on month.
- Lanxess announced another 550 job reductions. Roughly two-thirds were expected in Germany, extending the location adjustment beyond temporary idling.
- The chemical wage settlement delayed increases until 2027. The agreement traded near-term pay growth for a job-security fund—an unusually clear measure of cyclical weakness.
Strategic conclusion
The March shock changed the decision threshold for German plants. A site does not close because energy costs are high in one month. It closes when management no longer expects utilization and pricing to recover before the next major maintenance or investment cycle. The collapse in expectations therefore mattered more than the spot-price move itself.
2.Macroeconomic & Regulatory Landscape
Demand, energy, policy, and the Standort D cost stack
Production, sales, and employment
The VCI's fourth-quarter report, published on March 13, confirmed that 2025 had ended with chemical output down 3.3% for the year and capacity utilization at 72.5%. Chemicals and pharmaceuticals employed just under 478,000 people, down 0.5%, while chemical employment alone fell a little more than 1%.
The report's timing was unfortunate but analytically useful: it established that the Middle East shock had hit a sector already operating below its profitability threshold. The ifo survey then measured the deterioration. The chemical business climate fell to -25.0 from -16.7 in February. Employment expectations reached -32.1, the lowest value in the series. That was not a general German labor-market statistic. It was the sector's own forward assessment.
The collective agreement reached on March 25 made the adjustment concrete. Wages are scheduled to rise 2.1% in early 2027 and another 2.4% in 2028. Employers will contribute €300 per employee in both 2026 and 2027 to a job-security fund. The agreement did not cause the weak outlook. It revealed it.
Sources: VCI Q4 2025 report, ifo March chemical climate, Reuters — chemical wage agreement
Energy: a monthly shock with structural consequences
Destatis reported producer energy prices up 7.5% from February. The year-on-year comparison remained negative at -3.2%, which can look benign if read without the monthly move. For chemical companies, the sequence matters. Production decisions respond to current replacement costs, not to favorable base effects.
Oil-linked feedstocks and logistics transmitted the shock quickly. Companies announced substantial price increases for selected amines, polymers, silicones, and intermediates. The ability to execute those increases depended on product scarcity and customer switching costs. Basic chemicals with excess capacity remained exposed to margin compression.
The German industrial electricity subsidy was still pending at month-end. The government notified the European Commission on April 1. March plants therefore faced the shock without that instrument. Existing network-cost relief, electricity-tax reductions, and Strompreiskompensation softened the burden for eligible users but did not create a uniform five-cent electricity price.
Sources: Destatis producer prices, March, Financial Times — chemical price increases, Federal energy measures
Green Deal, REACH, and subsidies
On March 4, the European Commission proposed the Industrial Accelerator Act. The proposal sought to strengthen clean industrial capacity and demand for lower-carbon European products. The relevant tension for chemicals was immediate: local-content and resilience instruments can support demand, but compliance conditions add little value if plants cannot finance conversion.
On March 11, the Commission terminated the REACH restriction process for substances in single-use baby diapers. The narrow decision mattered as a governance signal: not every restriction proposal proceeds when the evidence and proportionality case are insufficient. That is how risk-based regulation should work.
Sources: European Commission — Industrial Accelerator Act proposal, European Commission — REACH restrictions
3.Corporate Movers & Shakers
Eight-company decision ledger and Standort D implications
| Company | March event | Standort D reading |
|---|---|---|
| BASF | 2026 strategy remained focused on savings and portfolio concentration; price increases followed the input shock | Ludwigshafen remained under cost pressure while the Zhanjiang Verbund was inaugurated |
| Bayer | FY2025 results; 2026 adjusted EBITDA guidance €9.6–10.1bn, with heavy litigation cash outflows expected | German operating case unchanged; litigation still set capital allocation |
| Covestro | XRG set €59.46 per share for the minority squeeze-out | Public-market exit advanced; German assets moved further into state-backed ownership |
| Evonik | Final FY2025 results confirmed adjusted EBITDA €1.87bn and 2026 range €1.7–2.0bn | Restructuring continued without a new March plant closure |
| Lanxess | FY2025 sales €5.67bn; EBITDA pre exceptionals €510m; 550 additional jobs to go, about two-thirds in Germany | Direct negative Standort D decision |
| Wacker Chemie | FY2025 sales €5.49bn; net loss €805m; no dividend; PACE savings target above €300m | Weak demand and energy costs accelerated domestic restructuring |
| Henkel | No material new M&A or closure announcement; Stahl process continued | Portfolio expansion continued, but March share-price weakness challenged the February optimism |
| Merck KGaA | FY2025 results; Life Science reorganization and leadership transition preparations | German headquarters retained strategic control; growth engines were global |
Lanxess was the cleanest cyclical signal. Sales fell 10.9%, and adjusted EBITDA fell 16.9%. Management expected improvement in the second half at the earliest and targeted €100 million of additional savings. The 550 job reductions followed from a cost base sized for demand that had not returned.
Wacker's €805 million net loss included substantial impairment and restructuring effects, but the dividend cancellation had a simpler message: cash preservation took priority. BASF's inauguration of the Zhanjiang Verbund in China, while Ludwigshafen remained in a multi-year savings program, sharpened the geographic comparison. German competence was still central. Marginal capacity growth was not.
Sources: Bayer FY2025, Covestro squeeze-out, Evonik FY2025, Lanxess FY2025, Wacker FY2025, Merck FY2025
4.Innovation & Transformation
From pilots and platforms to bankable industrial scale
The Circular Valley Convention in Düsseldorf on March 11–12 brought BASF, Bayer, Evonik, and Henkel together around circular business models. An AI and circular-economy conference in Cologne likewise connected materials companies with digital providers. These initiatives addressed a real bottleneck: circularity is partly a chemistry problem, but also a traceability, sorting, and contracting problem.
The limitation was economic. A pilot that converts waste or CO₂ into a product is not equivalent to a bankable industrial asset. Scale requires predictable feedstock, energy, carbon, and offtake prices. March made each of those variables more volatile.
Sources: Circular Valley Convention, AI & Circular Economy Conference
5.Financial, Narrative & Falsification Radar
Equities, analyst evidence, media language, and what would change the view
One-month equity performance
Method: February month-end to March month-end Xetra closes, unadjusted and rounded. Up is above +2%; Down below -2%; otherwise Neutral.
| Company | March performance | Trend |
|---|---|---|
| BASF | +7.6% | Up |
| Bayer | -6.2% | Down |
| Covestro | Takeover-capped near €59.46 | Neutral |
| Evonik | +13.3% | Up |
| Lanxess | -2.5% | Down |
| Wacker Chemie | +4.1% | Up |
| Henkel | -20.3% | Down |
| Merck KGaA | -16.1% | Down |
The dispersion matters more than the average. BASF and Evonik rose despite a deteriorating operating climate, consistent with product-price expectations and low starting valuations. Henkel and Merck gave back prior gains as investors questioned earnings resilience and deal economics. The market did not price a uniform chemical recovery.
Analyst-rating tape
Deutsche Bank recorded Bayer as Hold on March 5. The prior public entry was also Hold, so this was not an upgrade. No verified Goldman Sachs upgrade or downgrade for the eight-name universe was found in the March window. The evidentiary threshold here is deliberately strict: target-price commentary without a rating change is not counted as an upgrade or downgrade.
Price sources: BASF, Bayer, Covestro, Evonik, Lanxess, Wacker, Henkel, Merck KGaA. Rating source: Deutsche Bank recommendation history.
Headline and Mood Index
Media method: Public headlines and indexed snippets from Handelsblatt, FAZ, CHEManager, and Börsen-Zeitung were reviewed for vocabulary and emphasis. Paywalled or crawler-restricted text was not used as the sole support for a factual claim.
The headline vocabulary changed from “no recovery” to “shock.” Handelsblatt later summarized March as a collapse in sentiment with job losses threatening. CHEManager's editorial language stressed expensive energy, labor costs, regulation, and political inaction. FAZ and Börsen-Zeitung headline samples emphasized company results and market moves; neither supplied a credible recovery narrative.
| Keyword | March signal | Reading |
|---|---|---|
| Deindustrialization | Very high | Job cuts, China/Germany investment contrast, closure risk |
| Recovery | Very low | Restricted to selected share prices and scarcity pricing |
| Crisis | Very high | Energy shock, employment expectations at a historical low |
Sources: Handelsblatt — sentiment collapses, jobs threatened, CHEManager — Lone Voices in the Desert, Reuters — March ifo shock
What Would Change the View?
The March reading would improve if the energy shock proved short, price increases held without destroying volume, and employment expectations recovered. The opposite boundary condition is more severe: prolonged disruption through the Strait of Hormuz would convert a margin shock into a physical supply problem. March ended between those states. Neither was compatible with calling a recovery.